This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Octreoscan
- Generic Name
- Indium In-111 pentetreotide
- DrugBank Accession Number
- DB11835
- Background
Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Indium In-111 pentetreotide (DB11835)
- Weight
- Average: 1472.41
Monoisotopic: 1471.416070009 - Chemical Formula
- C62H80InN12O19S2
- Synonyms
- 111In-Pentetreotide
- 111Indium pentetreotide
- Indium (111In) pentetreotide
- Indium In 111 pentetreotide
- Indium In 111 Pentreotide
- Indium In-111 pentetreotide
- External IDs
- MP 1727
- MP-1727
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Diagnostic agent Metastatic neuroendocrine tumors •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Drink plenty of fluids.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Octreoscan Indium In-111 pentetreotide (10 ug/1mL) + Indium In-111 chloride (3 mCi/1mL) Kit Intravenous Mallinckrodt 2007-05-01 2017-07-01 US 
OCTREOSCAN Indium In-111 pentetreotide (10 mcg) + Indium In-111 chloride (111 MBq/ml) Injection, powder, for solution Intravenous Curium Netherlands B.V. 2014-07-08 Not applicable Italy 
Octreoscan Indium In-111 pentetreotide (10 ug/1mL) + Indium In-111 chloride (3 mCi/1mL) Kit Intravenous Curium US LLC 2015-10-14 Not applicable US
Categories
- ATC Codes
- V09IB01 — Indium (111in) pentetreotide
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Diagnostic Radiopharmaceuticals
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hypothalamic Hormones
- Indium (111In) Compounds
- Indium Radioisotopes
- Nerve Tissue Proteins
- Neuropeptides
- Pancreatic Hormones
- Peptide Hormones
- Peptides
- Pituitary Hormone Release Inhibiting Hormones
- Proteins
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Tumour Detection
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 139096-04-1
- InChI Key
- ZKZPXKKVDJOAIS-JWFOFJTQSA-J
- InChI
- InChI=1S/C62H84N12O19S2.In/c1-35(76)47(32-75)69-59(88)49-34-95-94-33-48(70-55(84)44(25-37-13-5-3-6-14-37)65-50(78)29-74(31-52(81)82)24-23-73(30-51(79)80)22-20-41(61(90)91)62(92)93)58(87)67-45(26-38-15-7-4-8-16-38)56(85)68-46(27-39-28-64-42-18-10-9-17-40(39)42)57(86)66-43(19-11-12-21-63)54(83)72-53(36(2)77)60(89)71-49;/h3-10,13-18,28,35-36,41,43-49,53,64,75-77H,11-12,19-27,29-34,63H2,1-2H3,(H,65,78)(H,66,86)(H,67,87)(H,68,85)(H,69,88)(H,70,84)(H,71,89)(H,72,83)(H,79,80)(H,81,82)(H,90,91)(H,92,93);/q;+3/p-4/i;1-4
- IUPAC Name
- (111In)indium(3+) ion 2-{[2-({[(1-{[10-(4-aminobutyl)-16-benzyl-4-[(1,3-dihydroxybutan-2-yl)-C-hydroxycarbonimidoyl]-6,12,15,18-tetrahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-9-oxido-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]methyl}(carboxymethyl)amino)ethyl](3,3-dicarboxypropyl)amino}acetate
- SMILES
- [111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Terminated Diagnostic Solid Tumors 1 1, 2 Terminated Diagnostic Gastroenteropancreatic Neuroendocrine Tumors 1 Not Available Completed Diagnostic Sarcoidosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous Kit Intravenous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6123916 No 2000-09-26 2017-09-26 US US5776894 No 1998-07-07 2015-07-07 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0217 mg/mL ALOGPS logP 1.24 ALOGPS logP 3.79 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 2.08 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 30 Chemaxon Hydrogen Donor Count 13 Chemaxon Polar Surface Area 530.22 Å2 Chemaxon Rotatable Bond Count 32 Chemaxon Refractivity 391.61 m3·mol-1 Chemaxon Polarizability 136.16 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 20, 2016 20:52 / Updated at December 01, 2022 11:27